S&P 500
(0.12%) 5 303.27 points
Dow Jones
(0.34%) 40 004 points
Nasdaq
(-0.07%) 16 686 points
Oil
(0.97%) $80.00
Gas
(5.73%) $2.64
Gold
(1.44%) $2 419.80
Silver
(6.36%) $31.78
Platinum
(2.18%) $1 094.70
USD/EUR
(-0.02%) $0.920
USD/NOK
(-0.18%) $10.68
USD/GBP
(-0.27%) $0.787
USD/RUB
(0.19%) $91.05

Realtime updates for ALX Oncology Holdings [ALXO]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
50.00%
return -6.19%
SELL
50.00%
return 0.08%
Last Updated17 May 2024 @ 16:00

-3.07% $ 14.21

SELL 134757 min ago

@ $14.58

Issued: 14 Feb 2024 @ 09:30


Return: -2.51%


Previous signal: Feb 12 - 14:52


Previous signal: Buy


Return: 1.02 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):
Profile picture for ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors...

Stats
Today's Volume 188 719
Average Volume 531 529
Market Cap 740.34M
EPS $0 ( 2024-05-09 )
Next earnings date ( $-0.840 ) 2024-06-12
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.83
ATR14 $0.0220 (0.15%)
Insider Trading
Date Person Action Amount type
2024-05-13 Randolph Sophia Sell 10 203 Common Stock
2024-05-13 Randolph Sophia Sell 1 797 Common Stock
2024-05-06 Pons Jaume Buy 20 000 Common Stock
2024-05-06 Pons Jaume Sell 20 000 Common Stock
2024-05-06 Pons Jaume Sell 20 000 Employee Stock Option (right to buy)
INSIDER POWER
83.00
Last 97 transactions
Buy: 3 614 697 | Sell: 629 979

Volume Correlation

Long: -0.22 (neutral)
Short: 0.75 (moderate)
Signal:(47.175) Neutral

ALX Oncology Holdings Correlation

10 Most Positive Correlations
VWE0.963
NAKD0.962
AYTU0.957
SIRI0.956
IBRX0.953
TENX0.953
GSMG0.952
LAWS0.952
UTHR0.951
JAGX0.947
10 Most Negative Correlations
NSIT-0.974
OVLY-0.971
SJ-0.97
GXII-0.967
BRIVU-0.963
TETC-0.961
MCAA-0.961
MLTX-0.961
ACVA-0.961
HERA-0.96

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ALX Oncology Holdings Correlation - Currency/Commodity

The country flag -0.51
( weak negative )
The country flag -0.64
( weak negative )
The country flag 0.00
( neutral )
The country flag -0.31
( neutral )
The country flag -0.49
( neutral )
The country flag -0.32
( neutral )

ALX Oncology Holdings Financials

Annual 2023
Revenue: $0
Gross Profit: $-836 000 (0.00 %)
EPS: $-3.74
FY 2023
Revenue: $0
Gross Profit: $-836 000 (0.00 %)
EPS: $-3.74
FY 2022
Revenue: $0
Gross Profit: $-1.47M (0.00 %)
EPS: $-3.03
FY 2021
Revenue: $0.00
Gross Profit: $0.00 (0.00 %)
EPS: $-4.52

Financial Reports:

No articles found.

ALX Oncology Holdings Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

ALX Oncology Holdings

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators